197 related articles for article (PubMed ID: 34978886)
1. Assessment
Yipsirimetee A; Chiewpoo P; Tripura R; Lek D; Day NPJ; Dondorp AM; Pukrittayakamee S; White NJ; Chotivanich K
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0148121. PubMed ID: 34978886
[TBL] [Abstract][Full Text] [Related]
2. Local emergence in Amazonia of
Mathieu LC; Cox H; Early AM; Mok S; Lazrek Y; Paquet JC; Ade MP; Lucchi NW; Grant Q; Udhayakumar V; Alexandre JS; Demar M; Ringwald P; Neafsey DE; Fidock DA; Musset L
Elife; 2020 May; 9():. PubMed ID: 32394893
[TBL] [Abstract][Full Text] [Related]
3. Gametocytes from K13 Propeller Mutant Plasmodium falciparum Clinical Isolates Demonstrate Reduced Susceptibility to Dihydroartemisinin in the Male Gamete Exflagellation Inhibition Assay.
Lozano S; Gamallo P; González-Cortés C; Presa Matilla JL; Fairhurst RM; Herreros E; Amaratunga C; Rodrigues J
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224530
[TBL] [Abstract][Full Text] [Related]
4. Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure.
Witmer K; Dahalan FA; Delves MJ; Yahiya S; Watson OJ; Straschil U; Chiwcharoen D; Sornboon B; Pukrittayakamee S; Pearson RD; Howick VM; Lawniczak MKN; White NJ; Dondorp AM; Okell LC; Chotivanich K; Ruecker A; Baum J
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139275
[TBL] [Abstract][Full Text] [Related]
5. Plasmodium berghei K13 Mutations Mediate
Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs.
Ng CL; Siciliano G; Lee MC; de Almeida MJ; Corey VC; Bopp SE; Bertuccini L; Wittlin S; Kasdin RG; Le Bihan A; Clozel M; Winzeler EA; Alano P; Fidock DA
Mol Microbiol; 2016 Aug; 101(3):381-93. PubMed ID: 27073104
[TBL] [Abstract][Full Text] [Related]
7. MEFAS, a hybrid of artesunate-mefloquine active against asexual stages of Plasmodium vivax in field isolates, inhibits malaria transmission.
Penna-Coutinho J; da Silva Araújo M; Campos Aguiar AC; Sá PM; Rios CT; Medeiros JF; Pereira DB; Boechat N; Krettli AU
Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():150-155. PubMed ID: 34637981
[TBL] [Abstract][Full Text] [Related]
8. Activity of Ivermectin and Its Metabolites against Asexual Blood Stage Plasmodium falciparum and Its Interactions with Antimalarial Drugs.
Yipsirimetee A; Tipthara P; Hanboonkunupakarn B; Tripura R; Lek D; Kümpornsin K; Lee MCS; Sattabongkot J; Dondorp AM; White NJ; Kobylinski KC; Tarning J; Chotivanich K
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0173022. PubMed ID: 37338381
[TBL] [Abstract][Full Text] [Related]
9. Role of Plasmodium falciparum Kelch 13 Protein Mutations in P. falciparum Populations from Northeastern Myanmar in Mediating Artemisinin Resistance.
Siddiqui FA; Boonhok R; Cabrera M; Mbenda HGN; Wang M; Min H; Liang X; Qin J; Zhu X; Miao J; Cao Y; Cui L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098812
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
Le Bihan A; de Kanter R; Angulo-Barturen I; Binkert C; Boss C; Brun R; Brunner R; Buchmann S; Burrows J; Dechering KJ; Delves M; Ewerling S; Ferrer S; Fischli C; Gamo-Benito FJ; Gnädig NF; Heidmann B; Jiménez-Díaz MB; Leroy D; Martínez MS; Meyer S; Moehrle JJ; Ng CL; Noviyanti R; Ruecker A; Sanz LM; Sauerwein RW; Scheurer C; Schleiferboeck S; Sinden R; Snyder C; Straimer J; Wirjanata G; Marfurt J; Price RN; Weller T; Fischli W; Fidock DA; Clozel M; Wittlin S
PLoS Med; 2016 Oct; 13(10):e1002138. PubMed ID: 27701420
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia.
Lanteri CA; Chaorattanakawee S; Lon C; Saunders DL; Rutvisuttinunt W; Yingyuen K; Bathurst I; Ding XC; Tyner SD
Antimicrob Agents Chemother; 2014 Oct; 58(10):5831-40. PubMed ID: 25049252
[TBL] [Abstract][Full Text] [Related]
12. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
[TBL] [Abstract][Full Text] [Related]
13. Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum.
Barnes KI; White NJ
Acta Trop; 2005 Jun; 94(3):230-40. PubMed ID: 15878154
[TBL] [Abstract][Full Text] [Related]
14. Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.
Ndayisaba G; Yeka A; Asante KP; Grobusch MP; Karita E; Mugerwa H; Asiimwe S; Oduro A; Fofana B; Doumbia S; Jain JP; Barsainya S; Kullak-Ublick GA; Su G; Schmitt EK; Csermak K; Gandhi P; Hughes D
Malar J; 2021 Dec; 20(1):478. PubMed ID: 34930267
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium species.
van Schalkwyk DA; Moon RW; Duffey M; Leroy D; Sutherland CJ
Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():5-11. PubMed ID: 34315108
[TBL] [Abstract][Full Text] [Related]
16.
Straimer J; Gnädig NF; Stokes BH; Ehrenberger M; Crane AA; Fidock DA
mBio; 2017 Apr; 8(2):. PubMed ID: 28400526
[TBL] [Abstract][Full Text] [Related]
17. Gametocyte clearance in uncomplicated and severe Plasmodium falciparum malaria after artesunate-mefloquine treatment in Thailand.
Tangpukdee N; Krudsood S; Srivilairit S; Phophak N; Chonsawat P; Yanpanich W; Kano S; Wilairatana P
Korean J Parasitol; 2008 Jun; 46(2):65-70. PubMed ID: 18552540
[TBL] [Abstract][Full Text] [Related]
18. The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound.
Bouwman SA; Zoleko-Manego R; Renner KC; Schmitt EK; Mombo-Ngoma G; Grobusch MP
Travel Med Infect Dis; 2020; 36():101765. PubMed ID: 32561392
[TBL] [Abstract][Full Text] [Related]
19. Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria.
Hien TT; White NJ; Thuy-Nhien NT; Hoa NT; Thuan PD; Tarning J; Nosten F; Magnusson B; Jain JP; Hamed K
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872070
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.
Atroosh WM; Al-Mekhlafi HM; Snounou G; Al-Jasari A; Sady H; Nasr NA; Lau YL; Surin J
Malar J; 2016 May; 15(1):295. PubMed ID: 27234587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
